These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25891945)

  • 21. Thermal expansion of organic crystals and precision of calculated crystal density: a survey of Cambridge Crystal Database.
    Sun CC
    J Pharm Sci; 2007 May; 96(5):1043-52. PubMed ID: 17455328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advances in the quantitative analytical methods of drug polymorphism].
    Ma LW; Du W; Zhao CS
    Yao Xue Xue Bao; 2011 Aug; 46(8):896-903. PubMed ID: 22007512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
    Almarsson O; Zaworotko MJ
    Chem Commun (Camb); 2004 Sep; (17):1889-96. PubMed ID: 15340589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation for the amorphous state of ER-34122, a dual 5-lipoxygenase/cyclooxygenase inhibitor with poor aqueous solubility, in HPMC solid dispersion prepared by the solvent evaporation method.
    Kushida I; Gotoda M
    Drug Dev Ind Pharm; 2013 Oct; 39(10):1582-8. PubMed ID: 22519663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solid form screening--a review.
    Aaltonen J; Allesø M; Mirza S; Koradia V; Gordon KC; Rantanen J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):23-37. PubMed ID: 18715549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of supramolecular structures in crystals on parallel stacking interactions between pyridine molecules.
    Janjić GV; Ninković DB; Zarić SD
    Acta Crystallogr B Struct Sci Cryst Eng Mater; 2013 Aug; 69(Pt 4):389-94. PubMed ID: 23873064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential molecular interactions between the crystalline and the amorphous phases of celecoxib.
    Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
    J Pharm Pharmacol; 2005 Oct; 57(10):1271-8. PubMed ID: 16259755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling the interplay of inter- and intramolecular hydrogen bonding in conformational polymorphs.
    Karamertzanis PG; Day GM; Welch GW; Kendrick J; Leusen FJ; Neumann MA; Price SL
    J Chem Phys; 2008 Jun; 128(24):244708. PubMed ID: 18601366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple approaches to pharmaceutical polymorphism investigation--a case study.
    Li H; Kiang YH; Jona J
    Eur J Pharm Sci; 2009 Dec; 38(5):426-32. PubMed ID: 19748574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blind crystal structure prediction of a novel second polymorph of 1-hydroxy-7-azabenzotriazole.
    Nowell H; Frampton CS; Waite J; Price SL
    Acta Crystallogr B; 2006 Aug; 62(Pt 4):642-50. PubMed ID: 16840814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformational polymorphism in organic crystals.
    Nangia A
    Acc Chem Res; 2008 May; 41(5):595-604. PubMed ID: 18348538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basic overview of chemoinformatics.
    Engel T
    J Chem Inf Model; 2006; 46(6):2267-77. PubMed ID: 17125169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intramolecular hydrogen bonding in medicinal chemistry.
    Kuhn B; Mohr P; Stahl M
    J Med Chem; 2010 Mar; 53(6):2601-11. PubMed ID: 20175530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Predicting" Polymorphs of Pharmaceuticals Using Hydrogen Bond Propensities: Probenecid and Its Two Single-Crystal-to-Single-Crystal Phase Transitions.
    Nauha E; Bernstein J
    J Pharm Sci; 2015 Jun; 104(6):2056-2061. PubMed ID: 25904460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of two polymorphs of lornoxicam.
    Zhang J; Tan X; Gao J; Fan W; Gao Y; Qian S
    J Pharm Pharmacol; 2013 Jan; 65(1):44-52. PubMed ID: 23215687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the solid-state forms of fenofibrate--a spectroscopic and computational study.
    Heinz A; Gordon KC; McGoverin CM; Rades T; Strachan CJ
    Eur J Pharm Biopharm; 2009 Jan; 71(1):100-8. PubMed ID: 18590814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QTAIM application in drug development: prediction of relative stability of drug polymorphs from experimental crystal structures.
    Abramov YA
    J Phys Chem A; 2011 Nov; 115(45):12809-17. PubMed ID: 21939257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.
    Heinz A; Strachan CJ; Gordon KC; Rades T
    J Pharm Pharmacol; 2009 Aug; 61(8):971-88. PubMed ID: 19703341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphic phase transitions: Macroscopic theory and molecular simulation.
    Anwar J; Zahn D
    Adv Drug Deliv Rev; 2017 Aug; 117():47-70. PubMed ID: 28939378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.